Biomedical subjects

V Hill

Publications and source records attributed to V Hill.

39 records · Page 3Linked to original sources

PubMedDate not supplied

Use of community genetic screening to prevent HFE-associated hereditary haemochromatosis.

HFE-associated hereditary haemochromatosis is a recessive, iron-overload disorder that affects about one in 200 north Europeans and that can be easily prevented. However, genetic screening for this disease is controversial, and so we assessed whether such screening was suitable for communities. Cheek-brush screening for the Cys282Tyr HFE mutation was offered to individuals in the workplace. Outcomes were assessed by questionnaires before and after testing. 11,307 individuals were screened. We recorded no increase in anxiety in individuals who were homozygous for the Cys282Tyr mutation or non-homozygous. Self-reported tiredness before testing was significantly higher in homozygous participants than in non-homozygous participants (chi2 test, p=0.029). Of the 47 homozygous individuals identified, 46 have taken steps to treat or prevent iron accumulation. Population genetic screening for HFE-associated hereditary haemochromatosis can be practicable and acceptable.

Adult↗

PubMedDate not supplied

M and N specific hemagglutinins of human erythrocytes stored in glucose solutions.

Alloagglutinins of M and N specificites with unique characteristics found in normal sera are described. Specific M or N agglutination by these sera occurred only when erythrocytes had been exposed to glucose-containing solutions. Conversion to the form of MN recognized by these sera required incubation of the cells in 1 to 2% glucose buffered to physiological or alkaline pH and was dependent on time and temperature of exposure, occurring in hours at 37 C and in days at 4 C. The sera appeared to be detecting an antigenic structure in which interaction between glucose and the amino group of the N-terminal amino acid of the MN receptor has produced a new specificity, analogous to the action of formaldehyde on N receptors and the resulting N-like structure detected by sera from hemodialysis patients.

Absorption↗

PubMedDate not supplied

Complicated urinary infection in spinal injury patients: fleroxacin compared with ciprofloxacin.

The efficacy and safety of fleroxacin and ciprofloxacin were evaluated in a single-centre, prospective, randomised, blinded study of patients with complicated urinary infection in a spinal injury unit. Patients were randomised to receive oral fleroxacin 400 mg once daily (n = 68) or oral ciprofloxacin 500 mg twice daily (n = 65) for 10 days. Clinical cure assessed 5-9 days after therapy was obtained in 41 of 42 (98%) assessable patients in the fleroxacin group, and in 41 of 43 (95%) of the ciprofloxacin group, and was maintained at the 6-week follow-up visit in all but 1 patient in each group. Bacteriological eradication rates 5-9 days after therapy exceeded 88% in the fleroxacin group and 86% in the ciprofloxacin group, and 69 and 65%, respectively, 6 weeks after completion of therapy. Adverse events occurred in a similarly low percentage of patients (19 and 20%) in both treatment groups, and consisted primarily of nausea. Once daily fleroxacin appears to be as safe and effective as twice daily ciprofloxacin and both represent efficacious treatment in complicated urinary infection in spinal injury patients.

Administration, Oral↗